Role of antimüllerian hormone as a biomarker of the menopausal transition

Iino, Kaori; Tarakida, Ayako; Abe, Kazuhiro; Taniguchi, Rin Ichiro; Higuchi, Tsuyoshi; Takahashi, Ippei; Mizunuma, Hideki

doi:10.1097/gme.0b013e3182611574

Cited by 14 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data may be of help to women contemplating the option of oocyte cryopreservation or to couples and individuals who are considering when to begin to try to conceive. While longitudinal studies exist and are in process regarding the predictive ability of AMH by age to forecast the final menstrual period [1,10], what is of interest to women of reproductive age who are seeking to become pregnant at a later age is their likelihood of success of conception. Therefore, continued research on the potential impact of the FMR1 gene on ovarian reserve (which includes the diagnostic value of AMH measurements) and fertility is important for providers of fertility care and their patients.…”

Section: Discussionmentioning

confidence: 99%

AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level

Pastore

McMurry

Williams

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level

Pastore

McMurry

Williams

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…About 15% of the female population faces infertility issues because of premature ovarian failure [ 26 ]. Anti-Müllerian hormone has been proven to be a sensitive biomarker for detecting the menopausal transition [ 27 ]. Another study [ 28 ] suggested that low serum anti-Müllerian hormone levels are an indication of early ovarian aging.…”

Section: Biomarkers Of Common Reproductive Impairments In Femalesmentioning

confidence: 99%

Developing a deeper insight into reproductive biomarkers

Wahid

Bashir

Bilal

et al. 2017

Clin Exp Reprod Med

View full text Add to dashboard Cite

The development of biomarkers of reproductive medicine is still in its infancy because many black boxes are still present in reproductive medicine. Novel approaches to human infertility diagnostics and treatment must be developed because reproductive medicine has lagged behind in the implementation of biomarkers in clinical medicine. Despite the dearth of the available literature, the current rapid pace of publications suggests that this gap will soon be filled therefore; this review is a précis of the research that has been done so far and will provide a basis for the development of biomarkers in reproductive medicine.

show abstract

“…Ethnicity also may influence serum AMH [39]. Interestingly, a recent study in 44 Japanese women demonstrated after AMH became undetectable, menopause onset was within 3 years [40], instead of 5 years shown by a study of large U.S. and European populations [41], although the study design and assay performance may contribute to these observational differences.…”

Section: Menopausementioning

confidence: 99%

Maximizing the clinical utility of antimüllerian hormone testing in women's health

Leader¹,

Baker

2014

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Purpose of reviewTo provide an update on the latest clinical applications of serum antimüllerian hormone (AMH) testing with practical approaches to mitigate the impact of significant variability in AMH results.Recent findingsRecent studies continue to demonstrate that AMH is the best single serum test for ovarian response management with, at most, a weak-to-moderate age-independent association with live-birth rate and time to conception. Data confirm serum AMH levels improve menopause prediction, monitoring of ovarian damage, and identification of women at risk for several ovary-related disorders such as polycystic ovary syndrome and premature or primary ovarian insufficiency. However, it is now recognized that serum AMH results can have dramatic variability due to common, biologic fluctuations within some individuals, use of hormonal contraceptives or other medications, certain surgical procedures, specimen treatment, assay changes, and laboratory calibration differences. Practical guidelines are provided to minimize the impact of variability in AMH results and maximize the accuracy of clinical decision-making.SummaryAMH is an ovarian biomarker of central importance which improves the clinical management of women's health. However, with the simultaneous rapid expansion of AMH clinical applications and recognition of variability in AMH results, consensus regarding the clinical cutpoints is increasingly difficult. Therefore, a careful approach to AMH measurement and interpretation in clinical care is essential.

show abstract

Role of antimüllerian hormone as a biomarker of the menopausal transition

Abstract: When AMH levels fall below detectable levels, women at the menopausal transition will progress to menopause within 3 years.

Cited by 14 publications

References 40 publications

AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level

AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level

Developing a deeper insight into reproductive biomarkers

Maximizing the clinical utility of antimüllerian hormone testing in women's health

Contact Info

Product

Resources

About